| Literature DB >> 26472689 |
Zhiheng Zhou1, Haibai Liu1, Caixia Wang2, Qian Lu3, Qinhai Huang1, Chanjiao Zheng1, Yixiong Lei1.
Abstract
Increasing evidence suggests that long non-coding RNAs (lncRNAs) are involved in a variety of physiological and pathophysiological processes. Our study was to investigate whether lncRNAs as novel expression signatures are able to modulate DNA damage and repair in cadmium(Cd) toxicity. There were aberrant expression profiles of lncRNAs in 35th Cd-induced cells as compared to untreated 16HBE cells. siRNA-mediated knockdown of ENST00000414355 inhibited the growth of DNA-damaged cells and decreased the expressions of DNA-damage related genes (ATM, ATR and ATRIP), while increased the expressions of DNA-repair related genes (DDB1, DDB2, OGG1, ERCC1, MSH2, RAD50, XRCC1 and BARD1). Cadmium increased ENST00000414355 expression in the lung of Cd-exposed rats in a dose-dependent manner. A significant positive correlation was observed between blood ENST00000414355 expression and urinary/blood Cd concentrations, and there were significant correlations of lncRNA-ENST00000414355 expression with the expressions of target genes in the lung of Cd-exposed rats and the blood of Cd exposed workers. These results indicate that some lncRNAs are aberrantly expressed in Cd-treated 16HBE cells. lncRNA-ENST00000414355 may serve as a signature for DNA damage and repair related to the epigenetic mechanisms underlying the cadmium toxicity and become a novel biomarker of cadmium toxicity.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26472689 PMCID: PMC4607885 DOI: 10.1038/srep15293
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1LncRNA and mRNA expression profiles and co-expression network in Cd-induced 35th cells (T) as compared to untreated 16HBE cells (C).
Hierarchical clustering was performed to show the distinguishable lncRNAs and mRNAs expression patterns in Cd-induced 35th cells (T) as compared to untreated 16HBE cells. (A) Differentially expressed lncRNAs and (B) differentially expressed mRNAs were detected. The A and B left panels showed the scatter-plot for T vs C. The A and B middle panels showed the volcano plot which was constructed using 2.0-fold up and down change values and p-values of 0.05. Red point in the plot represented the differentially expressed lncRNAs and mRNAs with statistical significance. The A and B right panels showed Hierarchical clustering for differentially expressed lncRNAs and mRNAs in T vs C. “Red” indicated high relative expression, and “blue” indicated low relative expression. (C) CNC network was constructed based on the correlation analysis between differentially expressed lncRNAs and mRNAs in Cd-induced 35th 16HBE cells as compared to untreated 16HBE cells. Triangle: lncRNA; circle: mRNA.
Figure 2Validation of miroarray findings by qPCR.
The expression of 10 lncRNAs were validated in untreated 16HBE cells, Cd-induced 5th, 15th treated cells, and 35th passage transformed cells by qPCR and normalized to that of β-actin. The fold change in expression was expressed as the expression in experiment group normalized to that in untreated 16HBE cells. Data are expressed as mean ± SD. *P < 0.05 vs untreated 16HBE cells (one-way ANOVA).
Figure 3Bioinformatics analysis of lncRNA-ENST00000414355.
(A) Co-expression network of LncRNA-ENST00000414355 and mRNA was constructed with cytoscopesoftware (http://www.cytoscape.org/) based on the correlation analysis between LncRNA-ENST00000414355 and differentially expressed mRNAs in Cd-induced 35th 16HBE cells as compared to untreated 16HBE cells. (B) GO and signaling pathway analysis of LncRNA-ENST00000414355. Pathway analysis was predominantly based on the KEGG database, and the mRNAs were annotated and classified according to the GO database.
DNA damage and its suppression during Cd-induced malignant transformation of 16HBE cells and siRNA/ENST00000414355 transfected 35th passage cells determined by comet assay.
| Cell type | DNA damage rate (%) | Tail length (μm) |
|---|---|---|
| Untransformed 16HBE cells | 4.75 | 12.8 ± 1.76 |
| 5th passage | 10.45# | 15.2 ± 3.54# |
| 15th passage | 22.00*# | 31.6 ± 2.80*# |
| 35th passage | 46.75* | 47.8 ± 2.36* |
| siRNA/ENST00000414355-4311 transfected 35th passage cells | 24.79*# | 33.8 ± 4.43*# |
| siRNA/ENST00000414355-4312 transfected 35th passage cells | 23.98*# | 32.4 ± 4.17*# |
| Negative control transfected 35th passage cells | 41.14* | 44.56 ± 5.17* |
The tail lengths of cells in which DNA damage was induced and suppressed were determined by comet assay in untransformed 16HBE cells, 5th, 15th, 35th passage transformed cells, siRNA/ENST00000414355 transfected 35th passage cells and Negative control transfected 35th passage cells. *P<0.05, vs untransformed controls, #P<0.05, vs 35th passage cells.
Figure 4mRNA expression of DNA damage and repair related genes in 16HBE cells with Cd induced malignant transformation and siRNA/lncRNA-ENST00000414355 transfected cells.
(A) mRNA expression of DNA damage and repair related genes in 16HBE cells with Cd induced malignant transformation. The gene expression was validated in untreated controls 16HBE cells, Cd-induced 5th, 15th treated cells, 35th passage transformed cells by qPCR and normalized to that of β-actin. The fold change in expression of experiment group was normalzied to that of untreated control 16HBE cells. Data are expressed as mean ± SD. *P < 0.05 vs untreated 16HBE (one-way ANOVA). (B) Untreated control 16HBE cells and Cd-transformed 35th passage cells were treated with lncRNA-ENST00000414355-siRNA, and the lncRNA-ENST00000414355 expression was detected after 72 h by qPCR. *P < 0.05 vs control cells (one-way ANOVA). (C) Untreated 16HBE cells and Cd-transformed 35th passage cells were independently treated with lncRNA-ENST00000414355-siRNA531 and siRNA532, and the mRNA expression of DNA damage related genes was detected after 48 h by qPCR. (D) Untreated 16HBE cells and Cd-transformed 35th passage cells were independently treated with lncRNA-ENST00000414355-siRNA531 and siRNA532, and the mRNA expression of DNA repair related genes was detected after 72 h by qPCR. *P < 0.05 vs control cells (one-way ANOVA).
Correlation between lncRNA-ENST00000414355 expression and its target gene expression in Cd-exposed rats.
| Target genes | Correlation coefficient (r) | P | Target genes | Correlation coefficient (r) | P |
|---|---|---|---|---|---|
| ATM | 0.653 | 0.001 | OGG1 | −0.737 | <0.0001 |
| ATR | 0.618 | 0.003 | ERCC1 | −0.531 | <0.0001 |
| ATRIP | 0.631 | <0.0001 | MSH2 | −0.529 | 0.002 |
| DDB1 | −0.701 | <0.0001 | RAD50 | −0.604 | <0.0001 |
| DDB2 | −0.685 | <0.0001 | XRCC1 | −0.652 | 0.004 |
Blood LncRNA-ENST00000414355 expression in Cd-exposed workers.
| Exposure to Cd at different levels | N | Blood lncRNA-ENST00000414355 concentration | F | P |
|---|---|---|---|---|
| Ucd levels | ||||
| 0–2 μg/g Cr | 153 | 0.993 ± 1.416 | 49.485 | <0.0001 |
| 2–5 μg/g Cr | 20 | 2.647 ± 3.578 | ||
| >5 μg/g Cr | 14 | 7.113 ± 5.467 | ||
| Urine β2-MG | ||||
| 0–500 μg/g Cr | 156 | 0.951 ± 1.720 | 70.329 | <0.0001 |
| 500–1000 μg/g Cr | 18 | 2.913 ± 1.383 | ||
| >1000 μg/g Cr | 13 | 7.969 ± 5.204 | ||
| BCd level | ||||
| 0–2 μg/l | 130 | 0.918 ± 1.214 | 37.324 | <0.0001 |
| 2–5 μg/l | 40 | 2.023 ± 3.558 | ||
| >5 μg/l | 17 | 6.126 ± 4.614 | ||
Figure 5Correlation analysis between lncRNA-ENST00000414355 expression and Cd concentration in Cd-exposed workers.
Correlation analysis between lncRNA-ENST00000414355 expression and blood Cd concentration (A), urine Cd concentration (B) and Urine β2-MG concentration (C). Blood lncRNA-ENST00000414355 expression was calculated by the ratio of its expression to that of β-actin. The urine cadmium concentration was normalized by urine creatinine (μg/L.Cr) and urine β2-MG (μg/g.Cr). The linear relationship was analyzed by Pearson correlation analysis.
Correlation Analysis between lncRNA-ENST00000414355 expression and target gene expression in Cd-exposed workers.
| Target genes | Correlation coefficient (r) | P | Target genes | Correlation coefficient (r) | P |
|---|---|---|---|---|---|
| ATM | 0.514 | <0.0001 | OGG1 | −0.719 | <0.0001 |
| ATR | 0.671 | 0.002 | ERCC1 | −0.417 | <0.0001 |
| ATRIP | 0.509 | 0.001 | MSH2 | −0.467 | <0.0001 |
| DDB1 | −0.743 | <0.0001 | RAD50 | −0.583 | 0.001 |
| DDB2 | −0.734 | <0.0001 | XRCC1 | −0.617 | 0.017 |
Primers used for Real-time PCR of selected lncRNAs and mRNA.
| LncRNAs | Primers |
|---|---|
| ENST00000414355 | Forward:5′−CAGAAAGAAGCCAAACAAGGAG−3′ |
| Reverse:5′− AACCACCAAACAGTCAGCAG−3′ | |
| ENST00000446135 | Forward: 5′−GGGACAAGCAGCACAGAACT−3′ |
| Reverse:5′− CAGCAGAATAACGGCACAAG−3′ | |
| ENST00000451446 | Forward: 5′−ATGATTGGCTCTTTCGCTGA−3′ |
| Reverse:5′− TCCACTTTCACAGGCATTTCT−3′ | |
| uc004bxy.1 | Forward: 5′−GAAAACTGCCCCACATCATC−3′ |
| Reverse:5′− GTGCTCTCCTTTGACCCTGT−3′ | |
| uc003tcy.3 | Forward: 5′−ATGGCGGTTTTGTCGAATAG−3′ |
| Reverse:5′− TGGACACAGCACATGTTTCA−3′ | |
| ENST00000439302 | Forward: 5′−TCCTTCCTTGAAGCCTAGCA−3′ |
| Reverse:5′− TCAGCAGCAGCAGAAGATGT−3′ | |
| AK000930 | Forward: 5′−CCAATGCAAGTGAACACGGG−3′ |
| Reverse:5′− TGGGATTTGCTGCATTTCACAG−3′ | |
| ENST00000436765 | Forward: 5′−GAAGTCCCCAGAAACATCCA−3′ |
| Reverse:5′− CAGGCCTTGATGCCTTAGAC−3′ | |
| ENST00000457776 | Forward: 5′−GTGTGTCCCCGAGAAAGTGT−3′ |
| Reverse:5′− TGCTAGGCTTCAAGGAAGGA−3′ | |
| AK021798 | Forward: 5′−TTTTTCATGCCGACTGTCCCT−3′ |
| Reverse:5′−GCACACAAAACCTACAAAACCTC−3′ | |
| mRNAs | Primers |
| ATM | Forward:5´- TGCCAGACAGCCGTGACTTAC -3´ |
| Reverse: 5´- ACCTCCACCTGCTCATACACAAG -3´ | |
| ATR | Forward: 5′-GCCGTTCTCCAGGAATACAG-3′ |
| Reverse: 5′-GAGCAACCGAGCTTGAGAGT-3′ | |
| ATRIP | Forward: 5′-CAGCTGGAGACAGAGATCAA-3′ |
| Reverse: 5′-GACATTCCAGCCAAGGTACT-3′ | |
| DDB1 | Forward: 5′-TGGTTGCCAAGCACCTACTA-3′ |
| Reverse: 5′-ACTGCGATCACCATGGAAGC-3′ | |
| DDB2 | Forward: 5′-ATCCTGTCAACGCAGCTTGT-3′ |
| Reverse: 5′-GATGCCAGGCTGCCTTGAT-3′ | |
| OGG1 | Forward: 5′- CCGAGCCATCCTGGAAGAAC-3′ |
| Reverse: 5′-CCATCAGGCAGATGCAGTCA-3′ | |
| ERCC1 | Forward: 5′-CTTGTCCAGGTGGATGTGAA-3′ |
| Reverse: 5′-GCCTTGTAGGTCTCCAGGTA-3′ | |
| MSH2 | Forward: 5′-CATCCAGGCATGCTTGTGTTGA-3′ |
| Reverse: 5′- GCAGTCCACAATGGACACTTC-3′ | |
| RAD50 | Forward: 5′-GGGTTTCCAAGGCTGTGCTAA -3′ |
| Reverse: 5′-TCTGACGTACCTGCCGAAGT-3′ | |
| XRCC1 | Forward: 5′-CAGCCGGATCAACAAGACAT-3′ |
| Reverse: 5′-CTGAGGAGGCAGCACTAGAA-3′ | |
| β-Actin | Forward: 5′-ACAGAGCCTCGCCTTTGCCGAT-3′ |
| Reverse: 5′-CTTGCACATGCCGGAGCCGTT -3′ |
Sequences of lncRNA-ENST00000414355 siRNA and scramble control siRNA.
| Name | lncRNA | Sequence(5′to 3′) |
|---|---|---|
| siRNA-4311 | ENST414355-sense | 5′-AGAAGCCAAACAAGGAGCUTT-3′ |
| siRNA-4311 | ENST414355-antisense | 5′-AGCUCCUUGUUUGGCUUCUTT-3′ |
| siRNA-4312 | ENST414355-sense | 5′-CCUAGGCACAGAUGCUAAUTT-3′ |
| siRNA-4312 | ENST414355-antisense | 5′-AUUAGCAUCUGUGCCUAGGTT-3′ |
| siRNA-4313 | ENST414355-sense | 5′-GGAGCUUUCUGCAGAAUGATT-3′ |
| siRNA-4313 | ENST414355-antisense | 5′-UCAUUCUGCAGAAAGCUCCTT-3′ |
| siRNA-NC | NC-sense | 5′-UUCUCCGAACGUGUCACGUTT-3′ |
| siRNA-NC | NC-antisense | 5′-ACGUGACACGUUCGGAGAATT-3′ |